TScan Therapeutics, Inc. (TCRX) — SEC Financial Statements & Analysis

TScan Therapeutics, Inc. (TCRX) is a biological products, (no diagnostic substances) company, incorporated in DE. TScan Therapeutics, Inc. trades on Nasdaq as: TCRX. TScan Therapeutics, Inc. (TCRX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-12. Based on that filing, TScan Therapeutics, Inc. carries a market cap of $127.35M, a P/E ratio of -1.08x, a P/B ratio of 1.85x, a P/S ratio of 17.91x, an enterprise value of $54.94M, and an EV/EBITDA multiple of -0.47x. On profitability, it posts a gross margin of 139.22%, an operating margin of -1695.15%, a net margin of -1655.35%, a Return on Equity (ROE) of -95.80%, a Return on Assets (ROA) of -50.09%, and a Return on Invested Capital (ROIC) of -230.72%. Per share, it reports EPS of $-0.91, diluted EPS of $-0.91, free cash flow per share of $-0.91, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 2.15% year-over-year, net income growth of -13.94% year-over-year, and EPS growth of -14.08% year-over-year. On the balance sheet, it maintains a current ratio of 3.37x, a quick ratio of 3.23x, working capital of $73.44M, a debt-to-equity ratio of 1.48x, a debt ratio of 0.6, an interest coverage ratio of -43.22x, free cash flow of $-118.44M (TTM), and net debt of $-72.41M. Figures sourced from SEC EDGAR.

Market Cap

$127.35M

P/E TTM

-1.08x

EPS TTM

$-0.91

P/B TTM

1.85x

ROE TTM

-95.80%

ROA TTM

-50.09%

Debt To Equity

1.48x

Free Cash Flow TTM

$-118.44M

Net Revenue TTM Growth 1Y

2.15%

Data as of 2026-06-30 · Source: SEC EDGAR